Product Information

BREO ELLIPTA 50-25 MCG INHALER is a brand product labeled by GlaxoSmithKline LLC, priced at $6.4835 per EA under NDC 00173091610. Its NADAC has been published 110 times since May 22, 2024.

BREO ELLIPTA 50-25 MCG INHALER

fluticasone furoate and vilanterol trifenatate
$6.4835per EA

Strength

50; 25 ug/1; ug/1

NDC

00173091610

Classification

Brand

Dosage Form

POWDER

Route

RESPIRATORY (INHALATION)

Last Updated

6/17/2026

Approval Type

New Drug (NDA)

FDA Application

NDA204275

On Market Since

5/12/2023

Pharmacological Classes

Adrenergic beta2-Agonists
Corticosteroid Hormone Receptor Agonists
Corticosteroid
beta2-Adrenergic Agonist

Price Statistics

The NADAC for BREO ELLIPTA 50-25 MCG INHALER has been published 110 times since May 22, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$6.4835 per EA
All-time high$6.5164 (Jun 12, 2024)
All-time low$6.4835 (Jun 17, 2026)
52-week high$6.4974
52-week low$6.4835
Median price$6.4980
Average price$6.4984
Largest weekly change-0.1% (Jun 19, 2024)
Weeks tracked110
Tracking sinceMay 22, 2024

Price History

1W

0.0%

1M

-0.0%

3M

-0.0%

6M

-0.1%

1Y

-0.2%

3Y

N/A

5Y

N/A

All

-0.5%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the fluticasone furoate and vilanterol trifenatate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Frequently asked questions

What is the NADAC price of BREO ELLIPTA 50-25 MCG INHALER?

The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 50-25 MCG INHALER, manufactured by GlaxoSmithKline LLC, is $6.4835 per EA (NDC 00173091610), effective Jun 24, 2026.

How has the price of BREO ELLIPTA 50-25 MCG INHALER changed over time?

Over the history we have for it, the NADAC for BREO ELLIPTA 50-25 MCG INHALER has held within roughly two percent of its current level. It has been tracked across 110 weekly CMS publications since May 22, 2024.

What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 50-25 MCG INHALER?

Since May 22, 2024, the NADAC for BREO ELLIPTA 50-25 MCG INHALER has ranged from a low of $6.4835 (Jun 17, 2026) to a high of $6.5164 (Jun 12, 2024), with a median of $6.4980 per EA.

Are there cheaper alternatives to BREO ELLIPTA 50-25 MCG INHALER?

No other NADAC-published product currently shares the active ingredient, strength, and dosage form of BREO ELLIPTA 50-25 MCG INHALER, so no direct lower-cost alternative is listed.

Who manufactures BREO ELLIPTA 50-25 MCG INHALER?

BREO ELLIPTA 50-25 MCG INHALER (NDC 00173091610) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.